• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cosmos Health Announces Application for Dual Listing on Upstream

    2/2/23 1:50:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email

    CHICAGO, IL / ACCESSWIRE / February 2, 2023 / Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").

    The planned dual listing on Upstream is designed to provide Cosmos Health the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, increasing liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed Cosmos Health.

    "Our application process to Upstream is yet another avenue we are exploring, in order to increase the liquidity of our stock by attracting international investors, and ultimately increasing shareholder value." stated Greg Siokas, Chief Executive Officer of Cosmos Health. "Given the global and innovative nature of our brands and products, it is important that we reach out to a global audience of investors who are not bound by geography or currency parameters, and Upstream is an important medium in that endeavor."

    Approval to be listed on Upstream is subject to acceptance by MERJ. However, as an existing NASDAQ issuer, Cosmos Health may qualify for an expedited listing process.

    About Upstream

    Upstream, a MERJ Exchange Market (merj.exchange), is a fully regulated global stock exchange for digital securities and NFTs. Powered by Horizon's proprietary matching engine technology, the platform enables users to trade digital securities and NFTs, and invest in securities for IPOs, crowdfunded companies, U.S. & international equities, and celebrity ventures using the Upstream app. For more information, please visit https://upstream.exchange.

    Cosmos Health Inc. (NASDAQ:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.

    Forward-Looking Statements

    With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations Contact:
    Lytham Partners, LLC
    Ben Shamsian
    E: shamsian@lythampartners.com
    P: 646-829-9701

    This press release shall not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted.

    NFTs received have no economic value, royalties, equity ownership, or dividends. NFTs are for utility, collection, and display only.

    *U.S. investors are not permitted to purchase Upstream listed securities. U.S. and Canadian citizens will only be able to trade in securities they currently own, that have been listed on Upstream, for liquidation purposes only.

    Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, and a full member of ANNA. MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agreed to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development stage companies. There can be no assurance the valuation of any particular company's securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.

    SOURCE: Cosmos Health Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/737916/Cosmos-Health-Announces-Application-for-Dual-Listing-on-Upstream

    Get the next $COSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency

    CHICAGO, June 23, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has signed an agreement to deploy an Artificial Intelligence (AI)-powered call center to support customer communications, including order intake and routine support functions, marking the latest step in the Company’s ongoing integration of AI across its operations. Under the agreement, the Company’s wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. ("CosmoFarm"), will deploy an AI-powered voice and communications platform to manage and enhance its customer communications. The

    6/23/26 3:35:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit

    Cumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners.Multi-year agreements extending up to 10 years provide recurring revenue and long-term cash flow visibility.Diversified across nine therapeutic categories, reducing dependence on any single product or partner.Produced at Cana’s 54,000 sq. ft., EU-GMP-licensed, EMA-certified Athens facility, following an approximately $5.5 million upgrade program and a new ACG capsule-filling line.Division expected to generate over $10 million in recurring annual profit at full capacity. CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos H

    6/22/26 10:30:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

    CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at C

    6/18/26 3:34:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Terzis Georgios bought $42,000 worth of shares (168,135 units at $0.25), increasing direct ownership by 8% to 2,235,398 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/17/26 9:15:35 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (218,447 units at $0.21), increasing direct ownership by 2% to 13,481,808 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/12/26 1:22:32 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $160,000 worth of shares (701,447 units at $0.23), increasing direct ownership by 6% to 13,263,361 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/12/26 6:20:31 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Terzis Georgios bought $42,000 worth of shares (168,135 units at $0.25), increasing direct ownership by 8% to 2,235,398 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/17/26 9:15:35 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (218,447 units at $0.21), increasing direct ownership by 2% to 13,481,808 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/12/26 1:22:32 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $160,000 worth of shares (701,447 units at $0.23), increasing direct ownership by 6% to 13,263,361 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    6/12/26 6:20:31 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

    S-3/A - Cosmos Health Inc. (0001474167) (Filer)

    6/5/26 8:37:59 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form DEFA14A filed by Cosmos Health Inc.

    DEFA14A - Cosmos Health Inc. (0001474167) (Filer)

    6/5/26 4:55:48 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form DEF 14A filed by Cosmos Health Inc.

    DEF 14A - Cosmos Health Inc. (0001474167) (Filer)

    6/2/26 4:30:20 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

    KEY HIGHLIGHTS Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C.Patent protection being pursued at national and regional levels across key international marketsTechnology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product developmentExpands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilitiesAligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Hea

    6/8/26 10:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care